



11 February 2026

cyclo**medica**
techn**egas**

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

NOTICE UNDER SECTION 708A(5) OF THE CORPORATIONS ACT 2001 (CTH)

On 4 February 2026, Cyclopharm Limited (the “**Company**”) announced a placement (“**Placement**”) of 14,736,842 new fully paid ordinary shares at \$0.95 per share raising A\$14 million before costs.

Cyclopharm is pleased to advise that it has completed a share placement to institutional investors of 9,473,684 new fully paid ordinary shares (“**T1 Placement Shares**”) at \$0.95 per share raising A\$9 million before costs. The Placement Shares were issued today.

The remaining 5,263,158 shares to be issued under the Placement (“**T2 Placement Shares**”) (representing A\$5 million) will be allotted on 25 February 2026, pending the receipt of settlement proceeds.

Accordingly, the Company advises:

- 1 The T1 Placement Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (Cth) (the “**Act**”).
- 2 This notice is being given under section 708A(5)(e) of the Act.
- 3 As at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (b) sections 674 and 674A of the Act.
- 4 As at the date of this notice, there is no excluded information as defined in sections 708A(7) and 708A(8) of the Act which is required to be disclosed by the Company.

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411